




Abbott Pakistan

Un-Audited Financial Statements for the
Quarter and Nine Months Ended September 30, 2013



 **Abbott**
A Promise for Life

Corporate Information

Board Of Directors

Munir A. Shaikh (Chairman)
Arshad Saeed Husain
(Chief Executive Officer)
Kamran Y. Mirza
Thomas C. Freyman
(Alternate Director Anis A. Shah)
Syed Anis Ahmed
Angelo Kondes
Shamim Ahmad Khan

Audit Committee

Shamim Ahmad Khan (Chairman)
Munir A. Shaikh
Kamran Y. Mirza
Maria Memon
(Chief Internal Auditor by Invitation)
Syed Anis Ahmed (CFO by Invitation)

Human Resource and Remuneration Committee

Munir A. Shaikh (Chairman)
Arshad Saeed Husain
Shamim Ahmad Khan
Shahrukh Masood

Share Transfer Committee

Arshad Saeed Husain (Chairman)
Syed Anis Ahmed
Anis A. Shah
(Alternate Director to Thomas C. Freyman)

Banking Committee

Munir A. Shaikh (Chairman)
Arshad Saeed Husain
Anis A. Shah
(Alternate Director to Thomas C. Freyman)
Syed Anis Ahmed

Chief Financial Officer

Syed Anis Ahmed

Company Secretary

Malik Saadatullah

Auditors

M. Yousuf Adil Saleem & Co.
Chartered Accountants

Legal Advisors

Orr, Dignam & Co.
SurrIDGE & Beecheno

Share Registrar

FAMCO Associates (Pvt) Ltd.
8-F, Next to Hotel Faran, Nursery, Block 6,
P.E.C.H.S, Shahrah-e-Faisal, Karachi.

Bankers

Faysal Bank Limited
Citibank N.A.
Deutsche Bank AG
MCB Bank Limited
National Bank of Pakistan
Standard Chartered Bank
(Pakistan) Limited
HSBC Bank Middle East Limited
The Bank of Tokyo-Mitsubishi UFJ Limited
Barclays Bank PLC

City Office

8th Floor, Faysal House,
St-02, Shahrah-e-Faisal, Karachi

Registered Office

Opposite Radio Pakistan
Transmission Centre,
Hyderabad Road, Landhi,
P.O. Box 7229, Karachi

Website

www.abbott.com.pk

Senior Management Team

Arshad Saeed Husain
(Chief Executive Officer)
Syed Anis Ahmed (Chief Financial Officer)
Anis A. Shah (Operations Director)
Ayub A. Siddiqui
(Head of Nutrition Division)
Habib Ahmed
(Head of Diagnostics Division)
Dr. Farrukh Hafeez
(Quality Assurance Director)
Shahrukh Masood
(Human Resource Director)
Seema Khan (Regulatory Director)
Dr. Sarmad Maqbool
(Marketing & Strategy Director)
Dr. Raef Ahmed (Medical Director)
Dr. Sheikh Adnan Lateef
(Head of Diabetes Care Division)
Dr. Suleman Alvi
(Business Development Director)

Directors' Report

The directors have pleasure in presenting their Report with the accounts of the Company for the third quarter ended September 30th, 2013.

FINANCIAL RESULTS

Sales for the quarter increased by 17% compared to the same quarter last year mainly driven by Pharmaceutical and Nutritionals.

Gross profit to sales ratio remained at 39%. Selling and distribution expenses increased 19% mainly due to inflation and escalation in energy cost. Administration expenses increased by 6% due to domestic inflation. Higher provision for Workers Profits Participation Fund, Workers Welfare Fund and Central Research Fund, in line with increased profit, led to an increase in other charges.

FUTURE OUTLOOK

The pharmaceutical industry is facing various challenges such as inflation. The continuous devaluation of the Pak Rupee and higher energy prices are of particular concern to the industry.

Considering inflation and the creeping devaluation of the Pak Rupee, we expect the Government of Pakistan to adopt a rational and transparent pricing mechanism in order to ensure continued access of pharmaceutical products to the market.

We look forward to the Government adopting a pragmatic approach, facilitating the industry to address its long outstanding issues.

Karachi: October 21st, 2013



Munir A. Shaikh
Chairman

Condensed Interim Balance Sheet

As at September 30, 2013

		UNAUDITED SEPTEMBER 30, 2013	AUDITED DECEMBER 31, 2012
	Note	----- (Rupees '000) -----	
Non-Current Assets			
Fixed Assets			
- Property, plant and equipment	3	3,029,151	2,629,154
- Intangible asset		45,920	58,835
		3,075,071	2,687,989
Long-term loans and advances		37,844	44,281
Long-term deposits		4,162	3,737
Long-term prepayments		5,627	6,491
		47,633	54,509
Total Non-Current Assets		3,122,704	2,742,498
Current Assets			
Stores and spares		115,479	121,844
Stock-in-trade		2,944,777	2,426,561
Trade debts		472,091	566,734
Loans and advances - considered good		286,996	123,308
Trade deposits and short-term prepayments		214,395	151,781
Accrued profit		4,121	2,973
Other receivables		96,496	80,766
Taxation recoverable		137,242	323,185
Cash and bank balances		3,460,091	2,790,212
		7,731,688	6,587,364
Current Liabilities			
Trade and other payables		2,883,550	2,432,911
		2,883,550	2,432,911
Net Current Assets		4,848,138	4,154,453
Total Assets Less Current Liabilities		7,970,842	6,896,951
Non-Current Liability			
Deferred taxation		168,227	189,557
Contingencies and Commitments	4		
NET ASSETS		7,802,615	6,707,394
FINANCED BY:			
Share Capital and Reserves			
Authorised capital			
200,000,000 ordinary shares of Rs.10 each		2,000,000	2,000,000
Issued, subscribed and paid-up capital	5	979,003	979,003
Reserves - capital		288,841	262,308
- revenue		6,534,771	5,466,083
SHAREHOLDERS' EQUITY		7,802,615	6,707,394

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE



SYED ANIS AHMED
DIRECTOR

Condensed Interim Profit and Loss Account (Unaudited)

For the Quarter and Nine Months Ended September 30, 2013

	Jul - Sep 2013	Jan - Sep 2013	Jul - Sep 2012	Jan - Sep 2012
	----- (Rupees '000) -----			
Sales - net				
Domestic	3,929,998	11,851,254	3,392,619	10,506,209
Export	235,290	529,351	167,991	476,214
	<u>4,165,288</u>	<u>12,380,605</u>	<u>3,560,610</u>	<u>10,982,423</u>
Service fee for toll manufacturing	1,314	8,214	5,894	14,038
	<u>4,166,602</u>	<u>12,388,819</u>	<u>3,566,504</u>	<u>10,996,461</u>
Cost of goods sold and services	2,527,465	7,580,604	2,237,190	6,811,454
	<u>1,639,137</u>	<u>4,808,215</u>	<u>1,329,314</u>	<u>4,185,007</u>
Gross profit				
Selling and distribution expenses	623,015	1,846,855	522,996	1,640,458
Administrative expenses	90,184	265,288	84,869	246,562
	<u>925,938</u>	<u>2,696,072</u>	<u>721,449</u>	<u>2,297,987</u>
Other operating income	66,578	190,098	44,120	132,656
Other operating charges	98,938	282,429	74,042	232,755
	<u>893,578</u>	<u>2,603,741</u>	<u>691,527</u>	<u>2,197,888</u>
Finance cost	667	2,058	740	1,437
	<u>892,911</u>	<u>2,601,683</u>	<u>690,787</u>	<u>2,196,451</u>
Profit before taxation				
Taxation				
- current	289,944	869,024	206,192	699,966
- deferred	(11,931)	(21,331)	(5,046)	(12,677)
	<u>278,013</u>	<u>847,693</u>	<u>201,146</u>	<u>687,289</u>
Profit for the period	<u>614,898</u>	<u>1,753,990</u>	<u>489,641</u>	<u>1,509,162</u>
	----- (Rupees) -----			
Earnings per share - basic / diluted	<u>6.28</u>	<u>17.92</u>	<u>5.00</u>	<u>15.42</u>

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE



SYED ANIS AHMED
DIRECTOR

Condensed Interim Statement of Comprehensive income (Unaudited)

For the Quarter and Nine Months Ended September 30, 2013

	Jul - Sep 2013	Jan - Sep 2013	Jul - Sep 2012	Jan - Sep 2012
	----- (Rupees '000) -----			
Profit for the period	614,898	1,753,990	489,641	1,509,162
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	<u>614,898</u>	<u>1,753,990</u>	<u>489,641</u>	<u>1,509,162</u>

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

Condensed Interim Cash Flow Statement (Unaudited)

For the Nine Months Ended September 30, 2013

		Jan - Sep 2013	Jan - Sep 2012
	Note	----- (Rupees '000) -----	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	6	2,548,125	1,950,749
Income taxes paid		(683,080)	(732,481)
Long-term loans and advances - net		6,437	(5,697)
Long-term deposits - net		(425)	-
Long-term prepayments - net		864	1,897
		<u>1,871,921</u>	<u>1,214,468</u>
Net cash inflow from operating activities		1,871,921	1,214,468
CASH FLOWS FROM INVESTING ACTIVITIES			
Fixed capital expenditure		(713,894)	(418,657)
Sale proceeds from disposal of fixed assets		22,863	20,606
Interest income		169,632	113,230
Net cash outflow from investing activities		(521,399)	(284,821)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance cost paid		(2,058)	(1,437)
Dividend paid		(678,585)	(653,523)
Net cash outflow from financing activities		(680,643)	(654,960)
Net increase in cash and cash equivalents		669,879	274,687
Cash and cash equivalents at the beginning of the period		2,790,212	1,453,327
Cash and cash equivalents at the end of the period		<u>3,460,091</u>	<u>1,728,014</u>

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE



SYED ANIS AHMED
DIRECTOR


Condensed Interim Statement of Changes in Equity (Unaudited)

For the Nine Months Ended September 30, 2013

	Reserves						Total Equity
	Share Capital	Capital Reserves		Revenue Reserves		Total	
		Reserve arising on Merger	Other	General Reserve	Un-appropriated Profit		
	(Rupees '000)						
Balance as at December 31, 2011	979,003	46,097	177,150	2,438,422	1,545,511	4,207,180	5,186,183
Transfer from unappropriated profit to general reserve made subsequent to the year ended December 31, 2011	-	-	-	1,150,000	(1,150,000)	-	-
Total comprehensive income for the nine months ended September 30, 2012							
Profit for the period					1,509,162	1,509,162	1,509,162
Other comprehensive income for the period, net of tax							
Total comprehensive income for the period	-	-	-	-	1,509,162	1,509,162	1,509,162
Transactions with owners, recorded directly in equity							
Final dividend for the year ended December 31, 2011 declared subsequent to the year end @ Rs. 4 per share	-	-	-	-	(391,601)	(391,601)	(391,601)
Interim dividend for the year ending, December 31, 2012 @ Rs. 3 per share	-	-	-	-	(293,701)	(293,701)	(293,701)
Capital contribution from Abbott International LLC, USA in relation to share based compensation	-	-	29,769	-	-	29,769	29,769
Balance as at September 30, 2012	979,003	46,097	206,919	3,588,422	1,219,371	5,060,809	6,039,812
Balance as at December 31, 2012	979,003	46,097	216,211	3,588,422	1,877,661	5,728,391	6,707,394
Transfer from unappropriated profit to general reserve made subsequent to the year ended December 31, 2012	-	-	-	1,750,000	(1,750,000)	-	-
Total comprehensive income for the nine months ended September 30, 2013							
Profit for the period					1,753,990	1,753,990	1,753,990
Other comprehensive income for the period, net of tax							
Total comprehensive income for the period	-	-	-	-	1,753,990	1,753,990	1,753,990
Transactions with owners, recorded directly in equity							
Final dividend for the year ended December 31, 2012 declared subsequent to the year end @ Rs. 4 per share	-	-	-	-	(391,601)	(391,601)	(391,601)
Interim dividend for the year ending, December 31, 2013 @ Rs. 3 per share	-	-	-	-	(293,701)	(293,701)	(293,701)
Capital contribution from Abbott International LLC, USA in relation to share based compensation	-	-	26,533	-	-	26,533	26,533
Balance as at September 30, 2013	979,003	46,097	242,744	5,338,422	1,196,349	6,823,612	7,802,615

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For the Nine Months Ended September 30, 2013

1. THE COMPANY AND ITS OPERATIONS

Abbott Laboratories (Pakistan) Limited (The Company) is a public limited company incorporated in Pakistan on July 2, 1948, and its shares are quoted on the Karachi, Lahore and Islamabad stock exchanges. The address of its registered office is opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of research based pharmaceutical, nutritional, diagnostic, diabetic care, molecular devices, hospital and consumer products and in providing toll manufacturing services.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

Statement of compliance

This condensed interim financial information has been prepared in accordance with the requirements of the International Accounting Standard 34 – “Interim Financial Reporting” and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed. This condensed interim financial information does not include all of the information and disclosures required for annual financial statements, and should be read in conjunction with the financial statements of the Company as at and for the period ended December 31, 2012.

This condensed interim financial information is unaudited.

2.2 Accounting policies

The accounting policies and the methods of computation adopted in the preparation of this condensed interim financial information are the same as those applied in the preparation of the financial statements for the year ended December 31, 2012.

2.3 Accounting estimates and judgments.

The preparation of condensed interim financial information in conformity with approved accounting standards, as applicable in Pakistan requires the management to make estimates, assumptions and use judgments that affect the application of policies and the reported amount of assets and liabilities and income and expenses.

Estimates and judgments made by management in the preparation of this condensed interim financial information are the same as those that were applied to the audited annual financial statements of the Company as at and for the year ended December 31, 2012.

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For the Nine Months Ended September 30, 2013

	UNAUDITED Jan - Sep 2013	UNAUDITED Jan - Sep 2012
	------(Rupees '000)-----	
3. PROPERTY, PLANT AND EQUIPMENT [COST OF ADDITIONS / (DELETIONS)]		
Plant and machinery	99,858 (14,135)	331,568 (17,901)
Buildings on freehold land	13,901	-
Office equipment	-	5,265
Vehicles	48,038 (42,358)	53,185 (30,009)
Computers	62,704 (812)	19,619 (47,234)
Demonstration equipment	305,377 (19,767)	115,995 -
Capital work in progress (CWIP) - net	188,562	(106,975)
Additions net off CWIP	<u>718,440</u>	<u>418,657</u>
Total (deletions)	<u>(77,072)</u>	<u>(95,144)</u>

4. CONTINGENCIES AND COMMITMENTS

4.1 Contingencies

4.1.1 The Company has given bank guarantees of Rs. 119.793 million (December 31, 2012: Rs 110.557 million) to the Customs Department, a utility company and other institutions against tenders.

4.1.2 The returns of total income for four tax years (Tax Years 2005 - 2008) were selected for audit by the tax authority. The Taxation Officer disallowed certain expenses claimed by the Company against which the Company filed appeals before the Commissioner Inland Revenue (Appeals) [CIR(A)]. The CIR(A) allowed certain expenses, however, maintained majority of the disallowances resulting in tax demand of Rs. 239.695 million. The Company has now filed the appeals before the Appellate Tribunal Inland Revenue (ATIR) which are pending adjudication.

Management is of the view that the position of the Company is sound and eventual outcome is expected to be in Company's favour. Therefore, no provision has been made in the condensed interim financial statements.

4.1.3 The Company has filed a reference application before the High Court of Sindh for assessment years 1997-98, 1999-00 to 2002-03 in respect of certain disallowances resulting in a tax demand of Rs 154.500 million, which is pending adjudication.

Management is of the view that the position of the Company is sound and eventual outcome is expected to be in Company's favour. However, being prudent, management has made a total provision of Rs. 140 million in this respect as of September 30, 2013 (December 31, 2012: Rs. 80 million).

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For the Nine Months Ended September 30, 2013

4.2 Commitments

4.2.1 Commitments for capital expenditure as at September 30, 2013 aggregated to Rs. 262.379 million (December 31, 2012: Rs. 127.907 million).

4.2.2 The Company has obtained short term financing facilities from various commercial banks amounting to Rs. 1,397 million (December 31, 2012: Rs. 1,372 million). These facilities can be utilized for letters of credit, guarantees and running finance / short term loans. However, the running finance / short term loan utilization cannot exceed Rs. 310 million (December 31, 2012: Rs. 310 million). The running finance / short term loan carries markup at rates ranging from KIBOR plus 1% to KIBOR plus 2% (December 31, 2012: KIBOR plus 1% to KIBOR plus 2%) and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not borrowed any amount against running finance / short term loan facilities at the balance sheet date. Commitments in respect of letters of credit as at balance sheet date aggregated to Rs. 427.778 million (December 31, 2012: Rs. 368.054 million).

5. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

As at September 30, 2013, Abbott Asia Investments Limited, UK held 76,259,454 (December 31, 2012: 76,259,454) shares. The ultimate holding company is Abbott International LLC, USA.

	UNAUDITED Jan - Sep 2013	UNAUDITED Jan - Sep 2012
Note	-----	-----
	(Rupees '000)	-----

6. CASH GENERATED FROM OPERATIONS

Profit before taxation	2,601,683	2,196,451
Adjustment for:		
Depreciation	293,529	232,219
Amortisation on intangible asset	12,915	12,915
Gain on disposal of fixed assets	(2,495)	(6,954)
Income on investments and deposits	(170,780)	(114,284)
Expense recognised in profit or loss in respect of equity-settled share-based payments	26,533	29,769
Finance cost	2,058	1,437
Working capital changes	6.1 (215,318)	(400,804)
	<u>2,548,125</u>	<u>1,950,749</u>

6.1 Working capital changes

(Increase) / decrease in current assets net of provision

Stores and spares	6,365	(14,791)
Stock-in-trade	(518,216)	(526,300)
Trade debts	94,643	(49,382)
Loans and advances	(163,688)	(117,712)
Trade deposits and short-term prepayments	(62,614)	(7,710)
Other receivables	(15,730)	(70,797)
	<u>(659,240)</u>	<u>(786,692)</u>

Increase in current liabilities

Trade and other payables - net	<u>443,922</u>	<u>385,888</u>
	<u>(215,318)</u>	<u>(400,804)</u>

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For the Nine Months Ended September 30, 2013

7. TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise other related parties, employee retirement benefit plans, directors and key management personnel. Transactions with related parties essentially entail sale and purchase of goods and services and expenses charged between these parties. Transactions with related parties are as follows:

	UNAUDITED Jan - Sep 2013	UNAUDITED Jan - Sep 2012
------(Rupees '000)-----		
Other related parties		
Sale of goods	69,398	47,641
Purchase of materials	1,417,972	2,133,372
Technical service fee	87,730	79,709
Reimbursements from a related party on account of:		
Selling and distribution expenses	48,728	44,186
Administrative expenses	5,347	6,356
Interest income earned	16,434	11,866
Charge in respect of staff retirement benefit plans:		
Pension fund	90,824	79,422
Provident fund	44,529	38,888
Key management personnel		
Short-term employee benefits	116,544	123,343
Post-employment benefits	13,807	12,885

8. SEGMENT ANALYSIS

8.1 Segment wise operating results for the third quarter:

	UNAUDITED				UNAUDITED			
	Jul - Sep				Jul - Sep			
	2013				2012			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
------(Rupees '000)-----								
Sales	3,128,979	743,865	421,945	4,294,789	2,614,712	594,551	451,363	3,660,626
Less:								
Sales return and discount	12,872	-	5,806	18,678	3,493	2,458	838	6,789
Sales tax and excise duty	-	74,077	36,746	110,823	-	55,833	37,394	93,227
Sales - net	3,116,107	669,788	379,393	4,165,288	2,611,219	536,260	413,131	3,560,610
Service fee for toll manufacturing	1,314	-	-	1,314	4,767	-	1,107	5,894
Cost of goods sold and services	3,117,421	669,788	379,393	4,166,602	2,616,006	536,260	414,238	3,566,504
	1,854,727	409,198	263,540	2,527,465	1,676,371	322,039	238,780	2,237,190
Gross profit	1,262,694	260,590	115,853	1,639,137	939,635	214,221	175,458	1,329,314
Selling and distribution expenses	436,587	78,859	107,569	623,015	374,762	73,398	74,816	522,996
Administrative expenses	74,447	11,392	4,345	90,184	71,882	9,198	3,789	84,869
Segment result	751,660	170,339	3,939	925,938	492,971	131,625	96,853	721,449

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For the Nine Months Ended September 30, 2013

8.2 Segment wise operating results for nine months:

	UNAUDITED				UNAUDITED			
	Jan - Sep				Jan - Sep			
	2013				2012			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
	(Rupees '000)							
Sales	9,277,586	2,063,189	1,391,530	12,732,305	8,312,657	1,636,719	1,352,857	11,302,233
Less:								
Sales return and discount	29,842	3,320	7,692	40,854	40,233	9,050	4,473	53,756
Sales tax and excise duty	-	193,702	117,144	310,846	-	150,800	115,254	266,054
Sales - net	9,247,744	1,866,167	1,266,694	12,380,605	8,272,424	1,476,869	1,233,130	10,982,423
Service fee for toll manufacturing	1,314	-	6,900	8,214	7,036	-	7,002	14,038
Cost of goods sold and services	9,249,058	1,866,167	1,273,594	12,388,819	8,279,460	1,476,869	1,240,132	10,996,461
	5,599,108	1,157,278	824,218	7,580,604	5,218,911	860,453	712,090	6,811,454
Gross profit	3,649,950	708,889	449,376	4,808,215	3,060,549	596,416	528,042	4,185,007
Selling and distribution expenses	1,329,482	266,411	250,962	1,846,855	1,205,119	228,300	207,039	1,640,458
Administrative expenses	217,599	36,780	10,909	265,288	205,803	30,301	10,458	246,562
Segment result	2,102,869	405,698	187,505	2,696,072	1,649,627	337,815	310,545	2,297,987

8.3 Reconciliation of segment results with profit before taxation

	UNAUDITED Jul - Sep 2013	UNAUDITED Jan - Sep 2013	UNAUDITED Jul - Sep 2012	UNAUDITED Jan - Sep 2012
	(Rupees '000)			
Total segment results	925,938	2,696,072	721,449	2,297,987
Other operating income	66,578	190,098	44,120	132,656
Other operating charges	98,938	282,429	74,042	232,755
Finance cost	667	2,058	740	1,437
Profit before taxation	892,911	2,601,683	690,787	2,196,451

8.4 Geographical information

Sales to external customers

	UNAUDITED Jan - Sep 2013	UNAUDITED Jan - Sep 2012
	(Rupees '000)	
Pakistan	11,859,468	10,520,247
Afghanistan	408,576	365,179
Srilanka	42,777	59,827
Netherlands	66,680	47,641
Bangladesh	8,600	3,567
Switzerland	2,718	-
	12,388,819	10,996,461

Selected Notes to the Condensed Interim Financial Information (Unaudited)


For the Nine Months Ended September 30, 2013

8.5 Segment Assets

	UNAUDITED				AUDITED			
	September 30, 2013				December 31, 2012			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
	(Rupees '000)							
Segment assets employed	5,555,990	414,102	961,435	6,931,527	4,723,188	254,297	745,981	5,723,466
Unallocated corporate assets				3,922,865				3,606,306
Total reported assets				<u>10,854,392</u>				<u>9,329,862</u>

9. DATE OF AUTHORISATION

This condensed interim financial information was authorised for issue on October 21, 2013 by the Board of Directors of the Company.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

ABBOTT LABORATORIES (PAKISTAN) LIMITED

Registered Office

Opposite Radio Pakistan
Transmission Centre, Hyderabad Road,
Landhi, P.O. Box 7229, Karachi
Phone :111-ABBOTT (111-222-688)
Fax: (92-21) 35001903

City Office

8th Floor, Faysal House,
St-02, Shahrah-e-Faisal, Karachi
Phone: (92-21) 32799018, 32799019
Fax: (92-21) 32800244
URL: www.abbott.com.pk

